| HUM |
Report |
Adjusted EPS |
BEAT |
pred ~$7.55 vs. cons $7.22 |
MEDIUM |
| HUM |
Report |
Insurance benefit ratio |
IN-LINE |
pred ~90.9% vs. cons 91.2% |
MEDIUM |
| HUM |
Report |
Revenue |
IN-LINE |
pred ~$40.85B vs. cons $40.61B |
HIGH |
| HUM |
Guide |
FY2026 adjusted EPS |
BETTER |
guide ~$9.50 vs. cons $8.94 (FY2026) |
MEDIUM |
| HUM |
Guide |
FY2026 Insurance benefit ratio |
BETTER |
guide ~92.50% vs. cons 92.75% (FY2026) |
MEDIUM |
| HUM |
Guide |
FY2026 revenue |
LOWER |
guide ~$161.0B vs. cons $162.19B (FY2026) |
MEDIUM |
| HUM |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.8% |
— |
MEDIUM |
| HUM |
Return |
5-day cumulative residual |
+2.0% (FADE) |
Day-1 residual of +3.8% fades to a five-day residual of +2.0%: favorable Q2 medical costs and a modest FY2026 raise support the initial move, but 2027 benefit reductions and likely membership attrition constrain out-period EPS revisions after the beat. |
MEDIUM |